Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug633 | Breastfeeding Support Provided to Mothers Through WhatsApp Messaging Application Wiki | 0.58 |
| drug631 | Brazilian Green Propolis Extract (EPP-AF) Wiki | 0.58 |
| drug632 | Breastfeeding Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001145 | Arrhythmias, Cardiac NIH | 1.00 |
| D016171 | Torsades de Pointes NIH | 0.58 |
| D001919 | Bradycardia NIH | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001678 | Atrioventricular block HPO | 0.58 |
| HP:0001664 | Torsade de pointes HPO | 0.58 |
| HP:0001662 | Bradycardia HPO | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0004757 | Paroxysmal atrial fibrillation HPO | 0.29 |
Navigate: Correlations HPO
There are 3 clinical trials
The objective of the study is to assess the impact of remote cardiac and vital sign monitoring in patients with coronavirus disease (COVID-19) in the outpatient setting.
Description: ac rhythm in patients with COVID-19 infection following treatment/discharge from MSH
Measure: Number of different arrhythmias Time: 7-14 DaysDescription: Temperature of patients with COVID-19 infection following treatment/discharge from MHS
Measure: Temperature Time: 7-14 DaysDescription: Oxygen saturation level in patients with COVID-19 infection following treatment/discharge from MSH
Measure: Oxygen Saturation Time: 7-14 DaysThe objective of the study is to estimate the frequency of cardiac arrhythmias and characterize the mode of death in patients with coronavirus disease (COVID-19). This is a single-center, retrospective/ prospective registry enrolling all COVID-19 positive patients at Mount Sinai Hospital. Patients who have been diagnosed with COVID-19 infection at Mount Sinai Hospital will be included.
Description: To characterize the frequency of cardiac arrhythmias in patients with COVID-19 infection
Measure: Frequency of cardiac arrhythmias Time: 19 MonthsDescription: To characterize the mode of death in patients with COVID-19 infection
Measure: Mode of death Time: 19 MonthsBACKGROUND AND RATIONALE: There is very limited literature available on the arrhythmia occurrence in the context of an infection by the SARS-CoV2 virus. On the other hand, treatment strategies against the SARS-CoV2 virus may carry a risk of QTc prolongation and pro-arrhythmia/sudden death which may be amplified by concomitant use of other QTc-prolonging drugs and/or ion disbalances. COVIDAR is an international initiative to monitor the occurrence of arrhythmic events in the context of the SARS-CoV2 infection, to identify potential modifiable predisposing factors to reduce their incidence and to inform the best arrhythmia management options in this patient population. MAIN OBJECTIVE: To describe the incidence and type of arrhythmic events in the context of the SARS-CoV2 infection. STUDY DESIGN: patient registry (observational). Patients will not undergo any additional investigations. Only data that is generated during routine clinical care will be collected. STUDY POPULATION: Patients admitted to the hospital highly suspected of or with confirmed COVID-19.
Description: Any arrhythmic event occurring in COVID-19 patients during hospital admission: Monomorphic ventricular tachycardia Polymorphic ventricular tachycardia/Torsades de pointes (non-sustained) Ventricular fibrillation AV-block Severe bradycardia, symptomatic and/or requiring treatment New-onset atrial fibrillation Other
Measure: Arrhythmia Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Categorical variable collecting the patient's underlying rhythm at baseline, on treatment and in case of arrhythmic adverse events): sinus rhythm, atrial fibrillation/flutter, other
Measure: Electrocardiographic changes - Underlying rhythm Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Collected as a categorical (normal, 1st-, 2nd- or 3rd degree AV block) and a continuous (PR duration in ms) at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Electrocardiographic changes - Atrioventricular conduction Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Collected as a continuous variable (ms) at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Electrocardiographic changes - QRS duration Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Collected as a categorical variable (not present, type 1 or type 2) at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Electrocardiographic changes - presence of Brugada QRS pattern Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Collected as a continuous variable (ms) at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Electrocardiographic changes - QTc duration Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Kalium, magnesium and calcium collected as continuous variables at baseline, on treatment and in case of arrhythmic adverse events). Will be reported as a categorical variable (presence/absence) of electrolyte misbalance
Measure: Laboratory abnormalities - electrolyte misbalance Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Cardiac CK, troponin T and/or troponin I (where available) collected as a continuous variable at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Laboratory abnormalities - cardiac biomarkers Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Creatinine clearance at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Laboratory abnormalities - renal function Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Liver enzymes collected at at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Laboratory abnormalities - liver function Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports